Early Detection Research Network


This biomarker is also known as:
  • N-Glycosylase/DNA Lyase,
  • MMH,
  • OGG1 Type 1d,
  • OGG1,
  • MUTM,
  • AP Lyase,
  • OGG1 Type 1f,
  • 8-Hydroxyguanine DNA Glycosylase,
  • 8-oxoguanine DNA glycosylase,
  • OGG1 Type 1e,
  • HMMH,
  • DNA-Apurinic Or Apyrimidinic Site Lyase,
  • HOGG1,
  • OGG1 Type 1g,
  • OGG1 Type 1h,
  • OGH1,


8-Oxoguanine DNA Glycosylase, or OGG1, is a DNA repair enzyme that removes both 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. OGG1 has a beta-lyase activity that nicks DNA 3' to the lesion. There are two major groups of splice variants for this gene, classified by alternative splicing of the C-terminal region of the gene, type 1 and type 2, depending on the last exon of the sequence. Type 1 alternative splice variants end with exon 7 and type 2 end with exon 8. All variants share the N-terminal region in common, which contains a mitochondrial targeting signal that is essential for mitochondrial localization.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Curated


OGG activity was lower in peripheral blood mononuclear cells from case patients than in those from control subjects. Low OGG activity is associated with an increased risk of lung cancer. Prospective studies are needed to validate these results.

Performance Comment

OGG1 has undergone Phase 2 validation. Work is in progress for Phase 3 validation.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.